Egetis Therapeutics investor relations material

Egetis Therapeutics develops and markets drugs for the treatment of rare and serious diseases in the orphan drug segment. Its main drug candidates currently include Aladote, a drug that reduces the risk of acute liver injury associated with acetaminophen/paracetamol poisoning and is being developed in phase IIb/III clinical trials; and Emcitate, a drug for the treatment of MCT8 deficiency (a rare inborn error of thyroid hormone signaling).